Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
RAPT Therapeutics (RAPT)
NASDAQ:RAPT
RAPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.79 - $10.37
Previous CloseN/A
Volume421.15K
Average Volume (3M)925.41K
Market Cap
$158.41M
Enterprise Value-$14.59M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.40
Next Earnings
Mar 06, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding132,006,820
10 Day Avg. Volume391,964
30 Day Avg. Volume925,415
Standard Deviation0.27
R-Squared0.00003
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.11
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
RAPT Therapeutics News
PremiumCompany Announcements
RAPT Therapeutics Plans Phase 2b Trials for RPT904
PremiumCompany Announcements
RAPT Therapeutics Announces Leadership Changes and Realignment
---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressRPT904 is partially de-risked with Phase 1 healthy volunteer data in China from Jemincare, and is being evaluated in ongoing Phase 2 trials in asthma and CSU in China.
Financial StabilityRAPT announced a $150 million private placement to shore up capital resources and fund their new clinical plans.
Market OpportunityRAPT highlighted the market opportunity for RPT904 in food allergy, with a significant number of individuals in the US and a strong potential for peak US sales.
Bears Say
CompetitionRAPT anticipates pricing erosion of 40% due to Xolair patent expiration and entry of biosimilar products, despite a potential price premium for RPT904.
Financial OutlookTarget price for RAPT has been lowered significantly due to reduced confidence in the CCR4 program.
Program TerminationUncertainty looms after termination of zelnecirnon program.
---
Ownership Overview
6.10% Insiders
23.74% Mutual Funds
25.11% Other Institutional Investors
39.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RAPT FAQ
What was RAPT Therapeutics’s price range in the past 12 months?
RAPT Therapeutics lowest stock price was $0.79 and its highest was $10.37 in the past 12 months.
What is RAPT Therapeutics’s market cap?
RAPT Therapeutics’s market cap is $158.41M.
When is RAPT Therapeutics’s upcoming earnings report date?
RAPT Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 13 days.
How were RAPT Therapeutics’s earnings last quarter?
RAPT Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.58 by $0.11.
Is RAPT Therapeutics overvalued?
According to Wall Street analysts RAPT Therapeutics’s price is currently Undervalued.
Does RAPT Therapeutics pay dividends?
RAPT Therapeutics does not currently pay dividends.
What is RAPT Therapeutics’s EPS estimate?
RAPT Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does RAPT Therapeutics have?
RAPT Therapeutics has 132,006,820 shares outstanding.
What happened to RAPT Therapeutics’s price movement after its last earnings report?
RAPT Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.58. Following the earnings report the stock price went down -0.571%.
Which hedge fund is a major shareholder of RAPT Therapeutics?
Currently, no hedge funds are holding shares in RAPT
---
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Blogger Sentiment
Bullish
RAPT Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 959.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.37%
12-Months-Change
Fundamentals
Return on Equity
-80.13%
Trailing 12-Months
Asset Growth
-45.69%
Trailing 12-Months
Company Description
RAPT Therapeutics
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
---
RAPT Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
BioCryst
―
Fate Therapeutics
―
Cara Therapeutics
―
Tonix Pharma
―
Arvinas Holding Company
―
Best Analysts Covering RAPT
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-25.44%
downgraded a sell rating 3 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -25.44% per trade.
---